The Cancer Letter

Inside information on cancer research and drug development

In Brief

City of Hope completes acquisition of CTCA

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

City of Hope has completed its previously announced acquisition of Cancer Treatment Centers of America (The Cancer Letter, Jan. 21, 2022). 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Oncology providers, advocates form LGBTQ+ community group at ASCO with focus on research, education, equity

“When I joined ASCO in 2001, the most important thing to me was networking. I savored the opportunities to come to the annual meeting to meet and to talk with those who had led the studies that would inform standards of care, particularly in gynecologic oncology,” said Don S. Dizon. 
By Don S. Dizon, Chunkit Fung, Paula Chambers Raney, Charles Kamen and Shail Maingi
In Brief

City of Hope, Charles R. Drew University of Medicine and Science launch new educational research and training program

City of Hope and Charles R. Drew University of Medicine and Science, the only Historically Black Graduate Institution west of the Mississippi River and one of only four Historically Black Medical Schools, announced the launch of a new partnership to educate a more diverse workforce in specialized medicine through internships, curriculum, training, mentorships, joint research projects, and more.
Clinical Roundup

Black patients who receive docetaxel for breast cancer experience less peripheral neuropathy than those who receive paclitaxel

Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center and the IU School of Medicine have discovered that Black patients with breast cancer who are treated with docetaxel experience less peripheral neuropathy. Their findings represent an important shift in knowledge about a patient population who’ve historically been underrepresented in breast cancer research.
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account